Sandoz Looks To Biosimilars As It Reprioritizes In The US
US Sandoz President Carol Lynch Talks Changing Portfolio
Executive Summary
Sandoz US president Carol Lynch talked to Scrip about its changing US portfolio, which will emphasize biosimilars, as the Novartis unit is poised to divest most of its US generics portfolio to Aurobindo.
You may also be interested in...
Sandoz Bolsters Respiratory Aspirations With Coalesce Acquisition
Sandoz is targeting growth opportunities in the respiratory complex generics space with the acquisition of UK-based drug delivery device firm Coalesce.
Sandoz And Aurobindo Cancel US Deal
Sandoz and Aurobindo have mutually agreed to terminate their billion-dollar agreement that would have seen the Indian company acquire Sandoz’ dermatology and oral solids businesses in the US, citing a delay in FTC approval for the deal.
Sandoz Gains Rights To Two US Injectables
With the $1bn deal to transfer its US dermatology and orals solids operations to Aurobindo still awaiting completion, Sandoz is expanding its portfolio of sterile injectables - a key area of focus for the company - by acquiring the rights to two products from BE Pharmaceuticals.